US 12,442,044 B2
Extract from a body fluid comprising a micro RNA
Takao Yasui, Aichi (JP); Daiki Takeshita, Aichi (JP); and Yoshinobu Baba, Aichi (JP)
Assigned to CRAIF INC., Tokyo (JP)
Filed by National University Corporation Tokai National Higher Education and Research System, Aichi (JP); and Craif Inc., Tokyo (JP)
Filed on Oct. 12, 2023, as Appl. No. 18/379,355.
Application 18/379,355 is a continuation of application No. 16/709,780, filed on Dec. 10, 2019, granted, now 11,845,975.
Claims priority of application No. 2018-248924 (JP), filed on Dec. 12, 2018.
Prior Publication US 2024/0110248 A1, Apr. 4, 2024
Int. Cl. C12Q 1/6886 (2018.01); G01N 33/493 (2006.01)
CPC C12Q 1/6886 (2013.01) [G01N 33/493 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/60 (2013.01)] 12 Claims
 
1. A method, comprising:
(a) providing a urine sample of a human subject;
(b) enriching the urine sample or a derivative thereof for at least miR-4521 to generate a urine extract using polymer precipitation;
(c) determining an amount of the miR-4521 in the urine extract;
(d) identifying the human subject as having a liver cancer or at an increased risk of having the liver cancer when the amount of the miR-4521 determined in (c) is greater than an amount of the miR-4521 in the urine extract of a control human subject that does not have the liver cancer; and
(e) administering an anticancer therapy comprising chemotherapy, surgery, immunotherapy, radiation therapy, or a combination thereof to the human subject.